[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Rennes University Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":681},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,47,0,25,[9,46,74,101,131,158,183,206,236,266,294,322,351,380,405,429,455,476,503,524,544,569,596,628,651],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100591703","ipstrauc--impact-on-care-pathways-of-a-new-management-of-cervical-trauma-in-conscious-patients-stable-in-pre-hospital-care-100591703",false,"NCT06983873","IPSTRAUC : Impact on Care Pathways of a New Management of Cervical Trauma in Conscious Patients Stable in Pre-hospital Care","Impact on Care Pathways of a New Management of Cervical Trauma in Conscious Patients Stable in Pre-hospital Care","IPSTRAUC","Inclusion Criteria:\n\nPATIENTS\n\n* GCS 15\n* Stable (no organ failure, SBP ≥ 90 mmHg, DBP ≥ 65 mmHg, RF between 10 and 24 cycles\u002Fmin)\n* Cooperative (calm and obedient to instructions)\n* Victim of a closed cervical spine trauma treated in the pre-hospital setting (fire brigade and\u002For Mobile Emergency and Resuscitation Service (SMUR)).\n* Recent trauma (\\\u003C 48 hours).\n* Care regulated by the Emergency Medical Service (SAMU).\n* Beneficiary of a social security scheme.\n* Who can be contacted by telephone\n* Have received oral and written information and have not objected to taking part in the study.\n\nPROFESSIONAL\n\n* Age ≥ 18 years\n* Professional firefighter or EMS regulating doctor\n* Professional who has received training in the protocol and, in the case of the experimental group, in the CCRa rules\n* Fluency in French\n* Having received oral and written information and not having objected to their participation in the study.\n\nExclusion Criteria:\n\nPATIENTS\n\n* Life-threatening organ damage\n* Cardiorespiratory arrest since the traumatic event in question\n* Polytrauma patient\n* Penetrating trauma or a supra-clavicular wound following a knife or firearm injury\n* Known spinal disease or previous spinal surgery (ankylosing spondylitis, rheumatic fever, spinal stenosis, cervical spine surgery).\n* Acute paralysis (paraplegia, tetraplegia, hemiplegia, hemiparesis or documented sensory or motor deficit)\n* Diagnosed osteogenesis imperfecta.\n* Patients not regulated by EMS or transported to a hospital not participating in the study\n* Pregnant or breast-feeding women\n* Known situation of deprivation of liberty (safeguard of justice), guardianship or curatorship\n\nPROFESSIONALS\n\n\\- Persons referred to in articles L. 1121-5 to L. 1121-8 and L. 1122-1-2 of the Public Health Code (e.g. minors, protected adults, persons deprived of their liberty, persons under guardianship, curatorship, etc.).","ALL","18 Years","65 Years",{"count":22,"type":23},840,"ESTIMATED","INTERVENTIONAL",[26],"NA","The aim of the study is to evaluate the application of Canadian C-Spine rules adapted to pre-hospital settings in France in order to improve the appropriateness of cervical spine immobilisation, reduce unnecessary imaging examinations and optimise patient care pathways.",[29,30,31,32],"Prehospital Emergency","Neck Injury","Neck Trauma","Emergency Medical Services","RECRUITING","2026-06-29",{"date":36,"type":37},"2026-06-30","ACTUAL",{"date":39,"type":37},"2026-06-17",{"date":41,"type":23},"2030-06",{"name":43,"class":44},"Rennes University Hospital","OTHER",14,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100576795","impact-of-ipe-in-multidisciplinary-primary-care-centres-on-collaborative-competency-of-healthcare-students-flirt-msp-100576795","NCT06789939","Impact of IPE in Multidisciplinary Primary Care Centres on Collaborative Competency of Healthcare Students (FLIRT-MSP)","Impact of Interprofessional Education in Multidisciplinary Primary Care Centres on Collaborative Competency of Healthcare Students - Quasi-experimental Study","FLIRT-MSP","Inclusion Criteria :\n\n* MPCC signatories to the interprofessional conventional agreement with the French national health insurance system.\n* Volunteer to take part in the FLIRT MSP Study.\n* MPCC with GPs who are habilitated to supervise internship family medicine students.\n* MPCC volunteer to receive healthcare students from different professions including at least one GP intern.\n* Volunteer to form an interprofessional training team.\n\nExclusion Criteria:\n\n* MPCC who are unable to form an internship training team or to commit to IPE as stipulated in the protocol will not be included in the MSP intervention group.\n* For the qualitative study, students who do not volunteer or are unavailable for interview will not be included in the FLIRT qualitative component.",{"count":55,"type":23},96,"OBSERVATIONAL","The aim of our study is to evaluate the impact of interprofessional education program (IPEP) for healthcare students in clinical placement in MPCC on interprofessional collaboration (IPC), comparing the acquisition of interprofessional collaboration skills in students receiving IPEP during their MPCC placement with those in their MPCC placements without this IPEP.\n\nThe IPEP will be delivered by trainers (health professionnals from the MPCC) who receive a train the trainer program.",[59],"Interprofessional Education",[61,62,63,64],"Primary Health Care","Interprofessional collaboration","Self evaluation program","Students","2026-06-23",{"date":67,"type":37},"2026-06-26",{"date":69,"type":37},"2025-01-02",{"date":71,"type":23},"2026-12",{"name":43,"class":44},26,{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":24,"phases":83,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},"100557271","phase-4-influence-of-human-albumin-supplementation-on-kidney-dysfunction-after-liver-transplantation-100557271","NCT06535945","Influence of Human Albumin Supplementation on Kidney Dysfunction After Liver Transplantation","HALT","Inclusion Criteria:\n\n* Male and female subjects equal or above 18 yrs old.\n* Recipients of primary liver allografts from a deceased donor (including after cardiac death) and as a single organ (liver only).\n* Capability of understanding the purpose and risks of the study.\n* Written informed consent\n\nExclusion Criteria:\n\n* Fulminant hepatitis\n* Kidney injury at baseline (Estimated Glomerular Filtration Rate \\\u003C 50 ml\u002Fmin in Modification of diet in renal disease-6) including hepatorenal syndrome\n* Use of an induction agent Basiliximab at liver transplantation\n* Protected person (adults legally protected, under judicial protection, guardianship, or supervision), person deprived of their liberty",{"count":82,"type":23},400,[84],"PHASE4","To verify whether albumin administration to achieve serum concentration above 30g\u002FL (treated group) and its maintenance within plasmatic physiologic range (above 30 g\u002FL) for five days diminishes rate of AKI at Day 7 after liver transplantation as compared to restrained albumin administration (when serum concentration is at 20 g\u002FL or below (control)).",[87,88],"Liver Transplantation","Acute Kidney Injury",[90,91,92,88],"Liver","Transplantation","Albumin","2026-06-16",{"date":39,"type":37},{"date":96,"type":37},"2025-03-26",{"date":98,"type":23},"2028-04-26",{"name":43,"class":44},8,{"id":102,"slug":103,"hasResults":12,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":12,"sex":18,"minAge":108,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":24,"phases":112,"briefSummary":113,"conditions":114,"keywords":116,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":130},"100523736","mima-pilot-study-microstructure-of-the-medial-temporal-lobe-in-early-alzheimers-disease-100523736","NCT06099587","MIMA Pilot Study: MIcrostructure of the Medial Temporal Lobe in Early Alzheimer's Disease","MIMA-P","Inclusion Criteria:\n\n* aged between 50 and 80\n* native French speaking\n* right-handed\n* with a level of education equal to or higher than the Certificat d'Etudes Primaires (primary school leaving certificate)\n* free of any medical or psychiatric condition likely to interfere with cognition, other than a diagnosis of SCD \u002F MCI\n* affiliated with a social security scheme\n* having received oral and written information abou the protocol and having signed a consent form to participate in this research\n* patients with 'subjective cognitive decline-plus' (hereafter 'SCD', criteria of Jessen et al., 2014) or patients with mild neurocognitive impairment due to Alzheimer's disease (hereafter 'MCI', criteria of Albert et al., 2011)\n\nExclusion Criteria:\n\n* contraindications to MRI : Abdominal circumference + upper limbs stuck to the body \\> 200 cm; Implantable pacemaker or defibrillator; Neurosurgical clips; Cochlear implants ; Neural or peripheral stimulator; Intra-orbital or encephalic metallic foreign bodies; Endoprostheses fitted less than 4 weeks ago and osteosynthesis devices fitted less than 6 weeks ago; Claustrophobia.\n* sensory deficit interfering with experimental tests\n* pregnant or breast-feeding women\n* adults under legal protection (safeguard of justice, curatorship, guardianship), persons deprived of liberty\n* 7-items modified Hachinski ischemic score \\>2 (Hachinski et al., 2012)\n* Dementia (McKhann et al., 2011)","50 Years","80 Years",{"count":111,"type":23},50,[26],"Patients with Mild Cognitive Impairment (MCI) or Subjective Cognitive Decline (SCD) may or may not develop Alzheimer's disease (AD) dementia. Yet identifying patients at risk is crucial: delaying the onset of the disease by 5 years could reduce prevalence by 50%. To achieve this, we need affordable biomarkers combined with clinically meaningful assessment tools. Current approaches (cognition, imaging or Tau and Amyloid peptide assays) lack precision or specificity (e.g., age-related memory deficits) and involve invasive and costly procedures, sometimes inaccessible in France (e.g., the \"AT(N)\" framework). Recently, quantitative diffusion MRI (dMRI) has identified in-vivo gray matter microstructural changes linked to hyperphosphorylated Tau protein, which are of great diagnostic value. Still, we ignore whether and how these changes are responsible for early memory impairment in AD. The MIMA-P project will combine multi-compartment models of the high-resolution diffusion signal with a cognitive assessment of memory based on recent models of medial temporal lobe function to assess the relevance of a new affordable, rapid and non-invasive early marker of the disease.",[115],"Alzheimer Disease, Early Onset",[117,118,119,120,121,122],"Alzheimer disease","Mild Cognitive Impairment","Subjective cognitive decline-plus","Diffusion MRI","Microstructure","Memory","2026-06-15",{"date":39,"type":37},{"date":126,"type":37},"2024-07-02",{"date":128,"type":23},"2029-03-02",{"name":43,"class":44},1,{"id":132,"slug":133,"hasResults":12,"nctId":134,"briefTitle":135,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":24,"phases":141,"briefSummary":142,"conditions":143,"keywords":147,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":152,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":130},"100461857","intestinal-organoids-100461857","NCT05294107","Intestinal Organoids","BIOÏDES","Inclusion Criteria:\n\n* Subjects aged 18 to 75 years\n* Subject undergoing endoscopy as part of the standard of care with the need to take digestive biopsy samples\n* Subject having signed a free and informed consent in writing\n\nExclusion Criteria:\n\n* Subjects under legal protection (safeguard of justice, curatorship or guardianship) or deprived of liberty.\n* Anticoagulant treatment and anti-platelet treatment (except for aspirin 75 mg)","75 Years",{"count":140,"type":23},90,[26],"Over the last decade, the use of mini-organ or organoids has been increasingly developed in fundamental research. Indeed, digestive organoids represent an essential advance compared to classical culture systems (epithelial cell lines, immortalized cells) since they preserve in culture the functional complexity present in vivo (architecture, different cell types). They also have the advantage of being able to be propagated indefinitely (unlike explants), minimizing the use of animal models and reducing the amount of tissue required. Finally, their growth and development depends on the origin of the sample (the organoid will develop differently if the cell source comes from a patient suffering from an inflammatory bowel disease, for example), thus generating models of human pathologies to better determine their physiopathology. The use of organoids in biomedical research has proven to be an indispensable tool for the understanding of cellular and molecular mechanisms involved in epithelial renewal and the screening of molecules and ingredients for applications in the health and agri-food sectors.",[144,145,146],"Digestive System Diseases","Inflammatory Bowel Disease, Ulcerative Colitis Type","Crohn Disease",[148,149,150,151],"biobank","organoids","digestive disease","inflammatory bowel disease",{"date":39,"type":37},{"date":154,"type":37},"2022-09-06",{"date":156,"type":23},"2028-03-07",{"name":43,"class":44},{"id":159,"slug":160,"hasResults":12,"nctId":161,"briefTitle":162,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":24,"phases":168,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":173,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":182},"100633535","pastrami--patient-specific-statistics-for-microstructure-augmented-connectomics-100633535","NCT07527949","PASTRAMI : Patient-specific Statistics for Microstructure-augmented Connectomics","PASTRAMI","Inclusion Criteria:\n\n1. Aged 18 to 60\n2. Admitted for moderate to severe non-penetrating head injury (with a Glasgow Coma Scale score ≤ 12)\n3. On mechanical ventilation and under continuous sedation\n4. Enrolled in a social security program\n5. Whose family has been informed and has signed a voluntary, informed, written consent form\n\nExclusion Criteria:\n\n1. History of head trauma, stroke, or neurodegenerative diseases\n2. A decision to limit active treatment has already been made\n3. Quadriplegia\n4. Contraindications to MRI\n5. Protected individuals (adults under legal protection \\[judicial protection, guardianship, conservatorship\\], individuals deprived of liberty, pregnant women \\[self-reported\\], breastfeeding women, and minors).","60 Years",{"count":167,"type":23},100,[26],"Traumatic brain injury (TBI) represent a major public health issue, accounting for approximately 1.5 million hospital admissions annually across the European Union and 160,000 cases in France. They are a significant cause of mortality and disability, with serious consequences for patients and their families. Predicting functional outcomes remains complex due to the heterogeneity of brain injuries, whether primary or secondary, as well as the mechanisms involved, particularly neuroinflammation. This difficulty is particularly pronounced for moderate to severe TBI, for which current predictive tools are still limited.\n\nThe PASTRAMI project proposes to utilise diffusion magnetic resonance imaging (MRI) to identify biomarkers associated with axonal lesions in the white matter. This technique enables the analysis of brain microstructure and the reconstruction of neural connections (connectome), thereby offering innovative prospects for improving the prediction of functional recovery.\n\nThis is a prospective, multicentre, interventional study involving 100 patients aged between 18 and 60 years with moderate to severe traumatic brain injury. The primary objective is to assess the prognostic value of brain microstructural measures at baseline, by correlating them with the GOSE functional score at 1 year. Secondary objectives include the analysis of mortality, functional outcome, quality of life, and early physiological factors influencing progression.\n\nPatients will undergo a standard MRI scan supplemented with additional sequences for prognostic purposes, without any change to their therapeutic management. The associated risks are minimal and relate primarily to the MRI scan. No immediate individual benefit is expected, but the results could improve our understanding of brain lesions and optimise future management.\n\nThe total duration of the study is 48 months. The expected outcomes include better characterisation of lesions and improved predictive tools, contributing to more appropriate clinical decisions.",[171,172],"Traumatic Brain Injury","Magnetic Resonance Imaging (MRI)","NOT_YET_RECRUITING","2026-06-11",{"date":176,"type":37},"2026-06-12",{"date":178,"type":23},"2026-09-01",{"date":180,"type":23},"2030-09-01",{"name":43,"class":44},2,{"id":184,"slug":185,"hasResults":12,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":12,"sex":18,"minAge":191,"maxAge":109,"enrollmentInfo":192,"targetDuration":4,"studyType":24,"phases":194,"briefSummary":196,"conditions":197,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":199,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":205},"100608541","phase-3-la-hcm-study--rivaroxaban-for-antithrombotic-prevention-in-hypertrophic-cardiomyopathy-patients-with-abnormal-left-atrial-strain-100608541","NCT07202897","LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.","LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain: A Randomized Multicenter Trial","LA-HCM","Inclusion Criteria:\n\n1. 40 - 80 years of age\n2. 50 and 120 kg of weight\n3. In sinus rhythm\n4. Prior confirmed diagnosis of \"primary\" hypertrophic cardiomyopathy\n5. Left Atrial reservoir strain measured ≤20% (corelab confirmation)\n6. Signature of an informed consent\n7. Highly effective contraceptive methods for women of childbearing potential from at least 14 days prior to start treatment, throughout the study treatment period, and until at least 4 weeks after the last dose of study medication\n\nExclusion Criteria:\n\n1. Secondary hypertrophic cardiomyopathy (aortic stenosis, hypertension, amyloidosis and all phenocopies…)\n2. Signs of heart failure\n3. Hospitalization\n4. Uncontrolled blood pressure\n5. Creatinine clearance \\\u003C30 mL\u002Fmin (Cockcroft)\n6. Severe liver dysfunction, cirrhosis Child B or C\n7. Any anticoagulation therapy in the 15 days prior to enrollment\n8. Any cardiac surgery in the 30 days prior to enrollment\n9. Documented atrial arrhythmia\n10. Any major bleeding in the 90 days prior to enrollment\n11. Need to be on dual antiplatelet therapy (aspirin \\>100 mg daily and a P2Y12 inhibitor, i.e. clopidogrel, ticagrelor, prasugrel…).\n12. Contraindication for a brain magnetic resonance imaging exam\n13. Known hypersensitivity or others contraindications to Rivaroxaban (refer to contraindications)\n14. Ischemic stroke or intracranial hemorrhage in the 30 days prior to enrollment\n15. Active endocarditis at the time of enrollment\n16. Concomitant combined strong P-gp and CYP3A4 inducers or inhibitors\n17. Active cancer or life expectancy less than 3 years\n18. Non-compliant\n19. Participation in another interventional clinical trial\n20. Protected person (adults legally protected (under judicial protection, guardianship or supervision), person deprived of their liberty, pregnant woman, lactating woman or planning pregnancy during the study period and minor)\n21. Absence of coverage by a social security scheme","40 Years",{"count":193,"type":23},532,[195],"PHASE3","Hypertrophic cardiomyopathy (HCM) is a common (\\> 1\u002F500 in the general adult population) genetically transmitted disease impacting markedly patients' lives from the early ages to the latest. The phenotype as the prognosis of HCM may greatly differ from one patient to another: most patients present no or few symptoms and a near-normal lifespan, while others are severely symptomatic. Paroxysmal, persistent or permanent atrial fibrillation (AF) is frequent in HCM, occurring in more than 20%-25% of patients and is often considered as an important turning point for the quality of life of these patients. AF decreases cardiac output and exercise tolerance, increases hospitalization rate, and markedly increase the risk of embolic stroke with the need for life-anticoagulation. It has been shown that stroke may precede AF discovery and that it may occur at young ages with devastation consequences. AF also may trigger sudden cardiac death.\n\nObservational studies have been conducted to search for parameters which correlate with the risk of AF (P wave duration and supra-ventricular burst on the Holter-ECG monitoring, L-wave morphology, degree of hypertrophy, clinical parameters-comorbidities, and size of the left atrium) with no real impact on clinical management. Left Atrial strain (LA-strain) has been recently demonstrated relevant (for instance our pilot work (for predicting stroke and\u002For AF (a cut-off of 15% is highly specific, 20% being the optimal cut-off). LA-strain (cut-off 20%) could be used for defining the patients that might require preventive anticoagulation therapy.\n\nA randomized clinical trial is needed to extend the use of anticoagulation therapy to patients in sinus rhythm but identified to be at risk for AF.\n\nOf note, it has been demonstrated that in this population, stroke occurred in 67% of the patients without any clinical atrial arrhythmia.",[198],"Hypertrophic Cardiomyopathy (HCM)",{"date":176,"type":37},{"date":201,"type":37},"2026-01-07",{"date":203,"type":23},"2033-01-07",{"name":43,"class":44},17,{"id":207,"slug":208,"hasResults":12,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":12,"sex":214,"minAge":19,"maxAge":215,"enrollmentInfo":216,"targetDuration":4,"studyType":24,"phases":217,"briefSummary":218,"conditions":219,"keywords":222,"overallStatus":173,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":130},"100642438","grace---genetic-insights-into-early-pregnancy-loss-using-cell-free-fetal-dna-100642438","NCT07639333","GRACE - Genetic Insights Into Early pRegnancy Loss Using Cell-free fEtal DNA","GRACE - Genetic Insights Into Early pRegnancy Loss: A Prospective Study Using Cell-free fEtal DNA","GRACE","Inclusion Criteria:\n\n* A stopped pregnancy with an intrauterine pregnancy diagnosed by ultrasound (embryo larger than 7 mm corresponding to a gestational age of 6 weeks and 5 days. This is justified by the fact that fetal fragment (FF) detection is possible at 5 weeks of gestation, or 7 weeks and 5 days)\n* Expulsion of a pregnancy within the last 2 hours\n\n  * Patient fluent in French\n  * Enrolled in a social security program\n  * Has received oral and written information about the protocol and has signed a consent form to participate in this research.\n\nExclusion Criteria:\n\n* Diagnosis of an empty gestational sac, ectopic pregnancy, or unknown location\n* Ultrasound findings consistent with a molar pregnancy\n* Identified cause (preimplantation diagnosis, multiple uterine fibroids or a single fibroid \\> 5 cm, uterine malformation affecting the uterine cavity, lupus, and antiphospholipid syndrome)\n* Inability to obtain a blood sample\n* Known current malignant tumor\n* Blood transfusions within the last 3 months\n* Cell therapy or immunotherapy within the last 3 months\n* Previous organ transplant","FEMALE","43 Years",{"count":167,"type":23},[26],"The aim of this study is to assess the impact of non-invasive prenatal testing right after an early isolated miscarriage on mental health and on the patient's subsequent care in the year following the miscarriage",[220,221],"Miscarriage in First Trimester","Prenatal Genetic Diagnosis",[223,224,225,226,227,228],"early miscarriage","miscarriage","prenatal diagnosis","prenatal test","cell free fetal DNA","chromosomal abnomarlities","2026-06-10",{"date":176,"type":37},{"date":232,"type":23},"2026-07",{"date":234,"type":23},"2029-01",{"name":43,"class":44},{"id":237,"slug":238,"hasResults":12,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":242,"eligibilityCriteria":243,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":244,"targetDuration":4,"studyType":24,"phases":246,"briefSummary":247,"conditions":248,"keywords":250,"overallStatus":173,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":265},"100638283","phase-4-intravenous-lidocaine-for-hepatectomy-100638283","NCT07590830","Intravenous Lidocaine for Hepatectomy","Effect of Perioperative Intravenous Lidocaine on Postoperative Opioid Related-side Effects After Open HEPatectomy: a Multicentre Prospective Randomized Controlled Study","ILHEP","Inclusion Criteria:\n\n* Inclusion criterion 1 : Age ≥ 18 years\n* Inclusion criterion 2 : Undergoing a scheduled surgery for open hepatectomy\n* Inclusion criterion 3 : Effective contraception in accordance with CFTG recommendations\n* Inclusion criterion 4 : Having received oral and written information about the protocol and having signed a consent form to take part in this research\n* Inclusion criterion 5 : Affiliated to a social security scheme\n\nExclusion Criteria:\n\n* Exclusion criterion 1 : Weight \\> 100 kg\n* Exclusion criterion 2 : Allergy or contraindication to lidocaine or one of its excipients and, in particular:\n\n  * Known hypersensitivity to lidocaine hydrochloride, to amide-type local anesthetics, or to any of the excipients (sodium chloride, sodium hydroxide solution or concentrated hydrochloric acid solution, water for injection)\n  * Treatment with following antiarythmic medication : class I, class III or Sotalol\n  * Heart failure NYHA grade 3-4, AV-block \\>1, without pacemaker\n  * Acute porphyria\n  * Recurrent porphyrias\n  * Uncontrolled epilepsy \u002F Seizure at enrollment\n* Exclusion criterion 3 : Allergy to one of the drugs used for anaesthesia or one of their excipients\n* Exclusion criterion 4 : Nefopam contraindication and, in particular:\n\n  * Renal insufficiency (Creatinine clearance \\\u003C 15 mL\u002Fmin)\n  * Untreated glaucoma\n  * Uncontrolled epilepsy\n  * Allergy\n* Exclusion criterion 5 : Ketoprofen contraindication and, in particular:\n\n  * Renal insufficiency (Creatinine clearance \\\u003C 50 mL\u002Fmin)\n  * Inflammatory bowel disease\n  * Allergy\n* Exclusion criterion 6 : Urgent surgery\n* Exclusion criterion 7 : Transplant surgery or transplanted patients\n* Exclusion criterion 8 : Surgery with planned regional anaesthesia\n* Exclusion criterion 9 : Patient with a preoperative Sp02 \\\u003C 95%\n* Exclusion criterion 10 : Obstructive sleep apnea syndrome\n* Exclusion criterion 11 : Severe hepatic insufficiency (Prothrombin Ratio \\\u003C 15%)\n* Exclusion criterion 12 : Patient with an ongoing opioid medication that will blur the results\n* Exclusion criterion 13 : Adults under legal protection (safeguard of justice, curatorship, guardianship), persons deprived of their liberty, pregnant or breast-feeding women, minors, persons unable to express their consent, persons hospitalized for a different reason\n* Exclusion criterion 14 : Known participation in other interventional research (RIPH1 or RIPH2)",{"count":245,"type":23},312,[84],"Liver resection is increasingly performed for hepatic tumors, mainly primary liver cancers and resectable metastases, but also for some benign lesions. Postoperative pain is often significant, regardless of the surgical technique, making effective pain control essential to promote early mobilization and reduce complications.\n\nCurrent standard care relies on multimodal analgesia, combining several drugs administered during surgery, with morphine administered as rescue therapy when required. Morphine is associated with side effects such as nausea, vomiting, ileus, hypoxemia, opioid-induced hyperalgesia, and transient cognitive impairment. Therefore, there is a need to optimize pain management while reducing opioid consumption and related adverse effects.\n\nIntravenous (IV) lidocaine has well-documented anti-inflammatory effects and is effective against neuropathic pain. Several studies have shown that intravenous lidocaine may be associated with improved analgesia, reduced opioid consumption, shorter hospital stay, and decreased postoperative ileus, nausea, and vomiting-particularly in abdominal and genitourinary surgeries. Therefore, Intravenous (IV) lidocaine may be a valuable alternative for postoperative pain management after liver surgery.\n\nNational guidelines now recommend perioperative Intravenous (IV) lidocaine for abdominal surgeries but its efficacy in liver surgery has not yet been established due to a lack of specific evidence (more specific data are needed). Findings from other types of abdominal surgery suggest a potential benefit, which should be confirmed by dedicated clinical trials and robust multicenter evaluation such as the ILHEP protocol.\n\nThe goal of this clinical trial is to assess the effect of intravenous perioperative lidocaine on postoperative opioid related-side effects and to formally confirm the safety of lidocaine during hepatic surgical procedures. The hypothesis is that Intravenous (IV) lidocaine compared with placebo (a look-alike substance that contains no drug e.g. a saline solution) would improve postoperative outcome by reducing opioid related side-effects in patients undergoing liver surgery and benefitting of the same baseline analgesia.\n\nIn the context of this trial, patients will receive either intravenous lidocaine or placebo according to their assigned randomization group during standardized general anesthesia, and will then be followed throughout their hospital stay until discharge or up to a maximum of 28 days.\n\nAn ancillary study will be conducted in patients enrolled at the coordinating center in Rennes to assess exposure to lidocaine during intravenous administration and to evaluate the relationship between blood concentrations and adverse events.",[249],"Hepatectomy",[251,252,253,254,255,249,256],"Lidocaine","Pain management","Analgesics","Postoperative opioid related-side effects","Double-Blind Method","Anesthesia","2026-05-12",{"date":259,"type":37},"2026-05-15",{"date":261,"type":23},"2026-08-01",{"date":263,"type":23},"2028-09-01",{"name":43,"class":44},9,{"id":267,"slug":268,"hasResults":12,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":272,"eligibilityCriteria":273,"healthyVolunteers":274,"sex":275,"minAge":19,"maxAge":276,"enrollmentInfo":277,"targetDuration":4,"studyType":24,"phases":278,"briefSummary":279,"conditions":280,"keywords":282,"overallStatus":173,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":130},"100627530","sperm-epigenome-in-hodgkin-lymphoma-100627530","NCT07449832","Sperm Epigenome in Hodgkin Lymphoma","Multiparametric Detection and Preventive Approaches of Cancer Treatment-induced Epigenetic Instability in the Male Germline.","SPELH","Inclusion Criteria:\n\n* Men aged 18 to 45 years\n* Diagnosed with Hodgkin lymphoma\n* Treatment-naïve to any cytotoxic therapy\n* Whose treatment regimen consists of 4 to 6 cycles of ABVD or BrECADD\n* Beneficiaries of the French social security system\n* Not opposed to participating in research\n\nExclusion Criteria:\n\n* Patient receiving abdominal radiotherapy",true,"MALE","45 Years",{"count":111,"type":23},[26],"Cancer treatments can have long-term effects on fertility. In men, scientific studies suggest that the process of sperm formation (spermatogenesis) may be disrupted even years after recovery, with potential consequences not only for fertility but also for the health of offspring. The effects of chemotherapy on sperm quality, particularly on DNA packaging (chromatin) and the epigenome, remain poorly understood. Therefore, further in-depth studies are needed to determine whether a history of cancer and chemotherapy treatment may impact the health of children fathered by young male survivors.\n\nWe therefore propose to conduct a clinical study aimed at better understanding the mechanisms by which chemotherapies affect spermatogenesis. The results could provide answers by identifying the effects of these drugs on the fertility of young male cancer patients in the long term and the sperm epigenome indicative of the health of the progeny.",[281],"Hodgkin Disease Lymphoma",[283,284,285],"epigenetic","chemotherapy","male gametes","2026-05-11",{"date":288,"type":37},"2026-05-14",{"date":290,"type":23},"2026-06-01",{"date":292,"type":23},"2030-01-01",{"name":43,"class":44},{"id":295,"slug":296,"hasResults":12,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":300,"eligibilityCriteria":301,"healthyVolunteers":274,"sex":18,"minAge":302,"maxAge":20,"enrollmentInfo":303,"targetDuration":4,"studyType":24,"phases":305,"briefSummary":306,"conditions":307,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":130},"100625823","effect-of-visual-deprivation-of-the-team-leader-on-team-performance-during-simulated-medical-emergencies-100625823","NCT07427641","Effect of Visual Deprivation of the Team Leader on Team Performance During Simulated Medical Emergencies","LEADE ME: Effect of Visual Deprivation of the Team Leader on Team Performance During Simulated Medical Emergencies - A Multicenter Randomized Controlled Study","LEAD ME","The teams participating in the simulation sessions are composed as follows:\n\n* A senior doctor identified as the \"medical leader\"\n* An anaesthesia and intensive care intern\n* A state-registered nurse anaesthetist\n\nInclusion Criteria:\n\n1. Participants with at least two years' experience in the specialty.\n\n   a. For interns, an additional requirement is that they must have completed a semester in intensive care.\n2. Recruited via simulation trainers at their respective hospitals or university hospitals.\n\nExclusion Criteria:\n\n* The study cannot be carried out during a safety rest period (i.e. the day after being on call).","25 Years",{"count":304,"type":23},54,[26],"This multicenter randomized controlled study aims to evaluate the impact of temporary visual deprivation of the medical team leader on non-technical skills and team performance during high-fidelity simulated medical emergencies. The intervention is based on principles of crisis resource management and cognitive load theory. Team performance will be assessed using validated scoring tools immediately after the intervention and at three months follow-up.",[308,309,310,311,312,313],"High Fidelity Simulation Training","Randomized Controlled Trials","Education, Medical, Continuing","Education, Medical","Teaching Innovation","Competency Based Education","2026-03-30",{"date":316,"type":37},"2026-03-31",{"date":318,"type":37},"2026-02-02",{"date":320,"type":23},"2027-04",{"name":43,"class":44},{"id":323,"slug":324,"hasResults":12,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":328,"eligibilityCriteria":329,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":330,"targetDuration":4,"studyType":24,"phases":332,"briefSummary":333,"conditions":334,"keywords":336,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":350},"100585110","evaluation-of-the-efficacy-of-e2r-hypnotherapy-in-the-management-of-chronic-insomnia-in-primary-care-hyperr-100585110","NCT06898099","Evaluation of the Efficacy of E2R Hypnotherapy in the Management of Chronic Insomnia in Primary Care (HypERR)","Evaluation of the Efficacy of E2R Hypnotherapy in the Management of Chronic Insomnia in Primary Care","HypERR","Inclusion Criteria:\n\n* Patient aged 18 or over,\n* Patient suffering from chronic insomnia according to the DSM-5 definition, whether or not treated with psychotropic drugs:\n\n  \\* At least one of the following sleep disorders: difficulty in falling asleep, difficulty in maintaining sleep, waking up too early and inability to go back to sleep, and \\* At least 3 nights a week for at least 3 months, and \\* In an adequate night-time sleep context, and \\* With at least one significant impact on, or impairment of, social, occupational or behavioral functioning, and \\* Insomnia not attributable to the physiological effects of a substance, and \\* Insomnia not explicable by a medical condition or mental disorder.\n* Patient willing to undergo hypnotherapy for 4 sessions of 30 min over 6 weeks,\n* Patient whose treating physician is the investigator,\n* Patient able to give free, informed, written consent,\n* Patient affiliated to the French social security system.\n\nExclusion Criteria:\n\n* Patients receiving or having received one or more hypnotherapy sessions (for any reason) in the last 5 years prior to inclusion,\n* Patient participating in another study involving the treatment of insomnia or another pathology having an impact on sleep disorders,\n* Patient unable to complete a self-administered questionnaire,\n* Patients with poor or no understanding of the French language,\n* Patients unable to attend hypnotherapy consultations,\n* Deaf or hard-of-hearing patients without hearing aids,\n* Patient under legal protection (safeguard of justice, curatorship, guardianship) or deprived of liberty,\n* Women declaring themselves pregnant or breastfeeding.",{"count":331,"type":23},136,[26],"In France, the treatment of chronic insomnia relies mainly on hypnotic drugs in routine care, despite the high level of iatrogenicity. Cognitive-behavioral therapy (CBT) is recommended by the HAS as a non-pharmaceutical first-line therapy for chronic insomnia. Despite evidence of their efficacy in chronic insomnia, these therapies remain underdeveloped in France (few practitioners, time-consuming for the patient). Hypnotherapy is another non-drug intervention suitable for routine outpatient care. Among the hypnosis methods practiced in France, E2R (Emotion, Regression, Repair) is a hypnotherapy method used in general practice, particularly for chronic insomnia. To date, no clinical trials have been carried out to demonstrate its effectiveness in this pathology.\n\nThe HypERR study is a multicenter, randomized, open-label study designed to evaluate the efficacy of a hypotherapy method called E2R in the management of chronic insomnia, by comparing it with standard care (without hypnosis).",[335],"Chronic Insomnia",[337,338,339,340,341],"chronic insomnia","E2R hypnosis","emotion-focused therapy","primary care","general medicine","2026-03-27",{"date":344,"type":37},"2026-04-02",{"date":346,"type":37},"2025-10-14",{"date":348,"type":23},"2027-04-14",{"name":43,"class":44},35,{"id":352,"slug":353,"hasResults":12,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":357,"eligibilityCriteria":358,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":138,"enrollmentInfo":359,"targetDuration":4,"studyType":24,"phases":361,"briefSummary":362,"conditions":363,"keywords":369,"overallStatus":173,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":375,"startDateStruct":376,"completionDateStruct":377,"leadSponsor":379,"locationsCount":130},"100576378","stroke-cerebral-reorganization-pathways-spectre-100576378","NCT06784518","Stroke Cerebral Reorganization Pathways (SPECTRE)","Stroke Cerebral Reorganization Pathways Longitudinal Study After Stroke of the Clinical Motor Pattern and the Cerebral Reorganization According to the Different Damaged Motor Pathways (Main and Accessory) (SPECTRE)","SPECTRE","Inclusion Criteria:\n\n* Adult (age greater than or equal to 18 years) less than 75 years of age, both sexes;\n* single supratentorial ischemic stroke confirmed by brain imaging\n* Upper limb deficit defined by a SAFE score \\\u003C5 (SAFE Stinear protocol, prognosis of post-stroke upper limb recovery) on D3 of stroke. This corresponds to the sum of shoulder abduction and finger extension according to the MRC (Medical Research Council) scale for each of these movements out of 5.\n* Absence of comprehension disorders limiting participation;\n* Patient covered by french social security;\n* Free, informed and written consent signed by the patient or a member of the patient's family (in the case of a patient who is able to understand the information and give consent but has motor difficulties resulting in an invalid signature).\n\nNon-Inclusion Criteria:\n\n* Multiple ischemic strokes or history of clinically significant stroke ;\n* Posterior fossa stroke ;\n* Hemorrhagic stroke;\n* Patient who have undergone thrombolysis or mechanical thrombectomy;\n* Extensive Fazekas grade 3 vascular leukopathy;\n* Pre-existing neurodegenerative pathology;\n* Patient with severe dyspnea or swallowing disorders who cannot undergo brain MRI;\n* Adults under legal protection (safeguard of justice, curatorship, guardianship, family habilitation), persons deprived of liberty;\n* Women declaring that they are pregnant or breast-feeding;\n* Patient participating in another therapeutic or drug intervention study that may have an impact on the effect of cerebral neuroplasticity on the SPECTRE study;\n* Patients with contraindications to MRI pacemaker or implantable defibrillator, neurosurgical clips, cochlear implants, intra-orbital or encephalic metallic foreign bodies, stents placed less than 4 weeks ago and osteosynthesis devices placed less than 6 weeks ago, claustrophobia.\n\nExclusion Criteria:\n\n* If the prognostic group according to the PREP2 algorithm (good, limited and poor) has already been reached during motor evoked potential assessment the patient is excluded.\n* Recurrence of clinically significant stroke (with worsening NIHSS score \\> 4) during study.",{"count":360,"type":23},30,[26],"SPECTRE is a prospective longitudinal study in order to identify whether patients with different degrees of motor recovery are distinguished by distinct brain post-stroke plasticity patterns in the acute and sub-acute phases. This study allows close longitudinal follow-up of patients with severe clinical motor impairment using functional MRI to study cerebral neuroplasticity after ischemic stroke in the acute and sub-acute phase in patients with upper limb motor impairement, taking into account prognostic criteria used in current practice.",[364,365,366,367,368],"Brain Diseases","Ischemic Stroke","Stroke","Brain Infarction","Stroke Rehabilitation",[370,371,372,373,374],"stroke","Rehabilitation","Upper Limb","Neuroplasticity","Connectivity",{"date":344,"type":37},{"date":178,"type":23},{"date":378,"type":23},"2029-03",{"name":43,"class":44},{"id":381,"slug":382,"hasResults":12,"nctId":383,"briefTitle":384,"officialTitle":385,"acronym":386,"eligibilityCriteria":387,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":388,"targetDuration":4,"studyType":24,"phases":390,"briefSummary":391,"conditions":392,"keywords":4,"overallStatus":173,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":404},"100629005","cle-pad--prevalence-of-pad-in-patients-with-surgically-lumbar-spinal-stenosis-100629005","NCT07469020","CLE-PAD : Prevalence of PAD in Patients With Surgically Lumbar Spinal Stenosis","CLE-PAD : Prevalence of Lower Extremity Peripheral Artery Disease in Patients With Surgically Lumbar Spinal Stenosis","CLE-PAD","Inclusion Criteria:\n\n* Presenting with a lumbar spinal stenosis with surgical indication, either unoperated or operated on less than 3 months ago\n* Affiliated with a social security scheme\n* Having received oral and written information about the protocol and having signed a written consent form to participate in this research.\n\nExclusion Criteria:\n\n* emergency surgical care\n* Contraindication to contrast enhanced CT scan\n\n  * Stroke or myocardial infarction (MI) within the last 3 months\n  * Known severe or poorly tolerated arrhythmia\n  * Known severe or symptomatic left ventricular outflow obstruction\n  * Decompensated heart failure\n  * History within the last 3 months of venous thromboembolic disease, myopericarditis, endocarditis, aortic dissection or intracardiac thrombus\n  * Severe uncontrolled hypertension (BP \\> 200\u002F110 mmHg)\n  * Inability to walk on the treadmill\n  * Major lower limb amputation\n  * Adult subject to legal protection",{"count":389,"type":23},49,[26],"The goal of this interventional study is to evaluate the rate of existing lower limb peripheral artery disease (PAD) in patients with surgically lumbar spinal stenosis (LSS). PAD and LSS can present similar symptoms and it can be difficult to diagnose PAD using conventional methods, depending on the location of the arterial disease. The main questions it aims to answer are :\n\n* What's the prevalence of PAD in LSS patients?\n* Which exam among routine tools is the most accurate to diagnose PAD in this population? Around their surgery for LSS (a few weeks before or after), participants will be included in a vascular medicine service. After checking of eligibility criteria, they will undergo a contrast-enhanced CT scan for the diagnosis of PAD and various routine diagnostic tests: Doppler ultrasound, treadmill tests, pressure index, pulse palpation.",[393,394,395],"PAD - Peripheral Arterial Disease","Lumbar Spinal Stenosis","Lower Limb Arterial Disease","2026-03-09",{"date":398,"type":37},"2026-03-13",{"date":400,"type":23},"2026-05",{"date":402,"type":23},"2026-08",{"name":43,"class":44},3,{"id":406,"slug":407,"hasResults":12,"nctId":408,"briefTitle":409,"officialTitle":409,"acronym":410,"eligibilityCriteria":411,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":109,"enrollmentInfo":412,"targetDuration":4,"studyType":24,"phases":414,"briefSummary":415,"conditions":416,"keywords":419,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":422,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":428,"locationsCount":130},"100507236","early-upper-limb-rehabilitation-with-eeg-neurofeedback-after-stroke-100507236","NCT05884762","earlY Upper Limb Rehabilitation WIth EEG-Neurofeedback After Stroke","YUWIN-Stroke","Inclusion Criteria:\n\n* Unilateral ischaemic or haemorrhagic stroke\n* Adult (18-80 years), both sexes\n* Stroke \\\u003C 3 weeks\n* Upper limb deficit defined by Shoulder Abduction Finger Extension score \\\u003C5 measured during the 7 days following stroke; i.e., patients predicted to have incomplete recovery\n* No participation-limiting comprehension problems\n* With or without homonymous lateral hemianopia; with or without visuospatial hemineglect\n* Free, informed and written consent signed by the patient or a member of the patient's family (in the case of a patient who is able to understand the information and give consent but has motor difficulties resulting in an invalid signature).\n* Affiliated to french social security\n\nExclusion Criteria:\n\n* Ischemic or hemorrhagic brain stem and\u002For cerebellum involvement\n* Multiple strokes\n* Stroke \\\u003C 1 week; in order not to be deleterious by starting active rehabilitation too early after immediate stroke\n* Aphasia with major comprehension impairment\n* Contraindication to MRI\n\n  * pacemaker or implantable defibrillator,\n  * neurosurgical clips,\n  * cochlear implants,\n  * intra-orbital or encephalic metallic foreign bodies,\n  * stents placed less than 4 weeks ago and osteosynthesis devices placed less than 6 weeks ago,\n  * claustrophobia. (Patients who have undergone thrombolysis or thrombectomy may be included in the study.)",{"count":413,"type":23},40,[26],"The aim of this study is to evaluate the effect of early rehabilitation treatment by electroencephalographic neurofeedback on upper limb motor function after stroke.\n\nResearchers will compare :\n\nInterventional group: electroencephalographic neurofeedback + traditional reference rehabilitation programme Control group: SHAM electroencephalographic neurofeedback + traditional reference rehabilitation programme",[366,417,418,368,367],"Stroke Hemorrhagic","Stroke, Ischemic",[366,371,420,372],"neurofeedback","2026-02-26",{"date":423,"type":37},"2026-03-03",{"date":425,"type":37},"2024-02-20",{"date":427,"type":23},"2027-11",{"name":43,"class":44},{"id":430,"slug":431,"hasResults":12,"nctId":432,"briefTitle":433,"officialTitle":434,"acronym":435,"eligibilityCriteria":436,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":437,"enrollmentInfo":438,"targetDuration":4,"studyType":24,"phases":440,"briefSummary":441,"conditions":442,"keywords":445,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":448,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":453,"locationsCount":454},"100497560","phase-3-rituximab-versus-ocrelizumab-in-relapsing-remitting-multiple-sclerosis-100497560","NCT05758831","RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.","A Prospective Randomized Trial of Non-inferiority Comparing RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis","TRIO","Inclusion Criteria:\n\n* Patients presenting a relapsing remitting MS according to Mac Donald 2017 criteria, with clinical or radiological criteria of activity (ie at least one relapse AND\u002FOR one new T2 lesion in the last 12 months before inclusion);\n* Age between 18 and 55 years\n* EDSS ≤ 5\n* Brain MRI within 6 months before inclusion\n* For women of childbearing potential\\*: effective contraception (effective contraception include oral contraception, intrauterine devices and other forms of contraception with failure rate \\\u003C1%, for the duration of the study and until 12 months after last dose administered) \\* A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy.\n\nA postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.\n\n* Having signed an informed consent form\n* Patients covered with social insurance\n\nNon-Inclusion Criteria:\n\n* Secondary or primary progressive MS;\n* Previous treatment by mitoxantrone, cladribine, alemtuzumab and anti CD20 therapies in the last two years;\n* Previous treatment by fingolimod or natalizumab in the last 4 weeks;\n* Treatment with high dose corticosteroids during the 30 days preceding the inclusion;\n* Occurrence of a relapse less than 30 days before inclusion;\n* Pregnancy or breastfeeding;\n* Other neurologic or systemic disease;\n* Concomitant participation or Participation in another therapeutic trial in the last 6 months;\n* Incapacity to understand or sign the consent form;\n* Contraindication to MRI;\n* Contraindication to anti-CD20 therapies:\n\n  * Receipt of a live or live-attenuated vaccine within 6 weeks prior to randomization\n  * Active malignancy.\n  * Any ongoing infection\n  * Severe heart failure (New York Heart Association Class IV) or severe uncontrolled cardiac disease\n  * Positive test for HIV, hepatitis B or C, or tuberculosis\n  * Severe immune deficiency:\n* Lymphopenia grade 3 (0.2 to 0.5 × 10\\^9\u002FL) or higher grades\n* Neutropenia grade 3 (0.5 to 1.0 × 10\\^9\u002FL) or higher grades\n\n  * Known hypersensitivity or other known side effects for any of the study medications, including co-medications such as high glucocorticosteroids\n  * AST or ALT \\>=3ULN\n  * Platelet (thrombocyte) count \\\u003C 100 x 10\\^9\u002FL\n* Adults legally protected (under judicial protection, guardianship, or supervision), persons deprived of their liberty.","55 Years",{"count":439,"type":23},386,[195],"The goal of this randomized clinical trial is to compare relapse remitting multiple sclerosis (RRMS) patients treated by ocrelizumab or by rituximab followed for 2 years. The main question it aims to answer is : • to demonstrate the non-inferiority of rituximab versus ocrelizumab in active relapsing MS patients on the % of patients without disease activity at 2 years.\n\nDuring the 2 years, the study includes 6 follow-up visits and the completion of various health and quality of life questionnaires. The protocol visits follow the usual schedule of treatment infusions for the disease (at initiation of treatment, 15 days after, and then every 6 months).\n\nTwo comparison groups: Researchers will compare rituximab treated patients versus ocrelizumab treated patients to see the % of patients without disease activity at 2 years.",[443,444],"Multiple Sclerosis","Relapsing-remitting Multiple Sclerosis",[443,446],"Relapsing-remitting","2026-01-29",{"date":318,"type":37},{"date":450,"type":37},"2023-06-01",{"date":452,"type":23},"2030-05-01",{"name":43,"class":44},23,{"id":456,"slug":457,"hasResults":12,"nctId":458,"briefTitle":459,"officialTitle":459,"acronym":460,"eligibilityCriteria":461,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":462,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":464,"conditions":465,"keywords":4,"overallStatus":173,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":468,"startDateStruct":470,"completionDateStruct":472,"leadSponsor":474,"locationsCount":475},"100619686","impact-on-mortality-of-hospitalisation-of-a-patient-in-a-hospital-bed-that-does-not-correspond-to-his-needs-after-a-visit-to-the-emergency-department-100619686","NCT07347847","Impact on Mortality of Hospitalisation of a Patient in a Hospital Bed That Does Not Correspond to His Needs After a Visit to the Emergency Department","RIGHT BED","Inclusion Criteria:\n\n* Presenting at an emergency department participating in the study,\n* Requiring hospitalisation\n\nExclusion Criteria:\n\n* Patients hospitalised in short-stay units with secondary outpatient care,\n* Adults subject to legal protection (legal guardianship, curatorship, trusteeship), persons deprived of their liberty.",{"count":463,"type":23},2766,"The aim of this study is to assess the impact of hospitalisation outside the referral requested by the emergency doctor on the mortality of patients admitted to emergency departments.",[466],"Emergency Department Patient","2026-01-16",{"date":469,"type":37},"2026-01-21",{"date":471,"type":23},"2026-01",{"date":473,"type":23},"2026-09",{"name":43,"class":44},7,{"id":477,"slug":478,"hasResults":12,"nctId":479,"briefTitle":480,"officialTitle":481,"acronym":482,"eligibilityCriteria":483,"healthyVolunteers":12,"sex":18,"minAge":484,"maxAge":485,"enrollmentInfo":486,"targetDuration":4,"studyType":24,"phases":487,"briefSummary":488,"conditions":489,"keywords":491,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":496,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":502,"locationsCount":404},"100565982","childhood-b-acute-lymphoblastic-leukaemia-and-role-of-cd9-gene-regulation-in-relapse-100565982","NCT06649253","Childhood B-acute Lymphoblastic Leukaemia and Role of CD9 Gene Regulation in Relapse","REALL CD9 : Molecular Mechanisms Involved in Relapses of Childhood B-acute Lymphoblastic Leukaemia, Role of Non-coding RNA in CD9 Gene Regulation","REALL CD9","Inclusion Criteria:\n\n* Under 18 years\n* With established diagnosis of B-ALL\n* Initial diagnosis made in the investigating centre\n* Having received oral and written information about the protocol, or oral only if the patient is unable to read.\n* Having signed a consent form if the patient is capable of giving informed written consent.\n* Whose legal guardians have received oral and written information about the protocol, and have signed a free, informed and written consent.\n* Beneficiary of a social security scheme\n\nExclusion Criteria:\n\n* Isolated extramedullary involvement at inclusion\n* Patient of childbearing age without effective contraception.\n* Adult subject to legal protection (safeguard of justice, curatorship, guardianship), person deprived of liberty.","0 Years","17 Years",{"count":111,"type":23},[26],"B-acute lymphoblastic leukaemia (B-ALL) is the most common cancer in children, with 20% of patients relapsing. CD9, a transmembrane protein, is linked to the migratory and adhesion capacities of leukaemia cells and could be associated with relapses. The aim of this project is to understand how CD9 regulation can be a marker of potential relapses, using bone and blood sampling of newly diagnosed patients at 3 crucial moments of therapy.",[490],"Leukemia, Lymphoblastic, Acute, Pediatric",[492,493,494],"CD9","miRNA","gene regulation","2025-12-31",{"date":497,"type":37},"2026-01-02",{"date":499,"type":37},"2025-03-22",{"date":501,"type":23},"2035-04",{"name":43,"class":44},{"id":504,"slug":505,"hasResults":12,"nctId":506,"briefTitle":507,"officialTitle":508,"acronym":509,"eligibilityCriteria":510,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":437,"enrollmentInfo":511,"targetDuration":4,"studyType":24,"phases":513,"briefSummary":515,"conditions":516,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":517,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":523,"locationsCount":182},"100561633","phase-1-allogenic-adipose-tissue-derived-mesenchymal-stromal-cells-for-the-treatment-of-primary-progressive-multiple-sclerosis-100561633","NCT06592703","Allogenic Adipose Tissue-derived Mesenchymal Stromal Cells for the Treatment of Primary Progressive Multiple Sclerosis","Allogenic Adipose Tissue-derived Mesenchymal Stromal Cells for the Treatment of Primary Progressive Multiple Sclerosis: an Open-label Phase I Clinical Trial.","MAESTRO-4MS","Inclusion Criteria:\n\n* Patient with Primary Progressive MS according to the criteria of Mc Donald 2017 (Thompson et al Lancet neurol, 2017)\n* Age between 18 and 55 years\n* EDSS score: 3 to 6 at inclusion\n* Documented evidence of disability progression independent of relapse activity at any point in time over the 2 years prior to the screening visit\n* Positive CSF with oligoclonal bands\n* For women of childbearing potential (WOCBP), effective contraception as per the CFTG recommendations (version 1.1)\n* Having signed a free, informed and written consent\n* Affiliated to social security scheme\n\nExclusion Criteria:\n\n* Inflammatory activity during the past year (relapses or new T2 MRI lesions)\n* Disease Modifying Drugs during the past year\n* Treatment with high dose corticosteroids during the 30 days preceding the inclusion\n* Contra indication to lumbar puncture\u002Fintrathecal infusion: intracranial hypertension, puncture site infections, severe thrombocytopenia (\\\u003C50 G\u002FL), anticoagulant or fibrinolytic treatment\n* Participation in another therapeutic trial in the last 6 months\n* Adults under legal protection (safeguard of justice, curatorship, guardianship), persons deprived of their liberty, pregnant or breastfeeding women, minors, persons unable to express their consent",{"count":512,"type":23},10,[514],"PHASE1","In this study, we propose, for the first time, to test the safety and the potential efficacy of repeated allogenic Adipose tissue-derived Mesenchymal Stromal Cells IT injections in Primary Progressive Multiple Sclerosis patients.",[443],{"date":518,"type":37},"2026-01-05",{"date":520,"type":37},"2025-03-06",{"date":522,"type":23},"2029-12",{"name":43,"class":44},{"id":525,"slug":526,"hasResults":12,"nctId":527,"briefTitle":528,"officialTitle":528,"acronym":529,"eligibilityCriteria":530,"healthyVolunteers":274,"sex":18,"minAge":108,"maxAge":109,"enrollmentInfo":531,"targetDuration":4,"studyType":24,"phases":533,"briefSummary":534,"conditions":535,"keywords":537,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":539,"startDateStruct":540,"completionDateStruct":542,"leadSponsor":543,"locationsCount":130},"100522287","network-based-biomarker-discovery-of-neurodegenerative-diseases-using-multimodal-connectivity-100522287","NCT06080659","Network-based biOmarker Discovery of Neurodegenerative Diseases Using Multimodal Connectivity","NODAL","Inclusion Criteria:\n\n* For all participants:\n* French mother tongue\n* right-handed\n* with a level of education equal to or higher than the Certificat d'Études Primaires (Primary School Certificate)\n* Free of any medical or psychiatric condition likely to interfere with cognition (excluding diagnosis for patients)\n* Affiliated with a social security scheme\n* Having received oral and written information about the protocol and having signed a consent form to participate in this research.\n\nDCS+ group:\n\n\\- Meeting the diagnostic criteria for \"subjective cognitive decline-plus\" (Jessen criteria (Jessen et al., 2014).\n\nAlzheimer's patients \"Mild Cognitive Impairment due to Alzheimer's Disease,\" \"MCI-MA\":\n\n\\- Meeting the diagnostic criteria for \"Mild neurocognitive disorder due to Alzheimer's disease\" (criteria of (Albert et al., 2011))\n\nDe novo\" Parkinsonian patients, \"MPdn\":\n\n\\- Presenting with newly diagnosed (\"de novo\") Parkinson's disease and free of cognitive deficits (criteria of Postuma et al., 2015 (Postuma et al., 2015))\n\nParkinsonian patients with \"Mild Cognitive Impairment, \"MCI-MP\":\n\n\\- Presenting Parkinson's disease associated with \"mild neurocognitive impairment\" (criteria of Litvan et al., 2012 (Litvan et al., 2012))\n\nExclusion Criteria:\n\n* All participants (healthy volunteers and patients)\n* Contraindications to MRI :\n* Abdominal circumference + upper limbs sticking to the body \\> 200 cm;\n* Implantable pacemaker or defibrillator;\n* Neurosurgical clips;\n* Cochlear implants ;\n* Neural or peripheral stimulator;\n* Intra-orbital or encephalic metallic foreign bodies;\n* Endoprostheses fitted less than 4 weeks ago and osteosynthesis devices fitted less than 6 weeks ago;\n* Claustrophobia.\n* Pregnant or breast-feeding women;\n* Adults under legal protection (safeguard of justice, curatorship, guardianship), persons deprived of liberty.\n\nPatients only\n\n* Score \\>2 on the modified Hachinski scale (Hachinski et al., 2012)\n* Dementia according to McKhann criteria (McKhann et al., 2011)\n* Sensory deficit interfering with experimental tests\n\nHealthy volunteers only\n\n\\- Cognitive impairment (MoCA score \\\u003C 26)",{"count":532,"type":23},120,[26],"The aim of the NODAL clinical trial is to demonstrate the feasibility of new, low-cost, non-invasive biomarkers of neurodegenerative pathologies as early Alzheimer and Parkinson, based on the estimation of the multimodal connectome.",[115,536],"Parkinson Disease",[538],"connectome",{"date":518,"type":37},{"date":541,"type":37},"2023-11-06",{"date":71,"type":23},{"name":43,"class":44},{"id":545,"slug":546,"hasResults":12,"nctId":547,"briefTitle":548,"officialTitle":549,"acronym":550,"eligibilityCriteria":551,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":552,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":554,"conditions":555,"keywords":558,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":563,"startDateStruct":564,"completionDateStruct":566,"leadSponsor":567,"locationsCount":568},"100338520","platelet-inhibitor-treated-patients-with-head-injury-trauma-meeting-nice-criteria--is-the-ct-scan-mandatory--100338520","NCT03687528","Platelet Inhibitor Treated Patients With Head Injury Trauma Meeting NICE Criteria : is the CT-scan Mandatory ?","Platelet Inhibitor Treated Patients With Head Injury Trauma Without Any Clinical Symptoms of Cerebral Haemorrhage (NICE Criteria) : is the CT-scan Mandatory ?","TCAP","Inclusion Criteria:\n\n* At least 18 years old\n* Patient with a head injury trauma, described by the patient or seen at the clinical exam\n* Glasgow score between 13 and 15 at the clinical exam\n* Current treatment with antiplatelet inhibitors\n* Informed non opposition form signed\n\nExclusion Criteria :\n\n* Absence of CT-scanner\n* Patients with double anti-platelet aggregation\n* Patients on anticoagulants",{"count":553,"type":23},3200,"At the emergencies rooms, patients with head trauma meeting one of the NICE criteria, which include antiplatelet inhibitors treatment, are considered as patients with a risk of cerebral haemorrage and are taken systematically for a CT-scanner.\n\nHowever, there are more and more antiplatelet inhibitor's patient with minor head injury traumas seen at the emergencies room and the efficiency of this NICE criteria is controversial on litterature.\n\nThis study aims to determine that the absence of no other NICE criteria than antiplatelet inhibitors is a sufficient condition to eliminate a cerebral haemorrhage for patients with head injury traumas, and conversely, that antiplatelet inhibitors treatment would not be by itself an indication for a CT-scanner.",[556,557],"Head Injury Trauma","Emergencies",[559,560,561,562],"emergencies","platelet inhibitors","minor head injury trauma","CT-scan",{"date":518,"type":37},{"date":565,"type":37},"2020-06-15",{"date":71,"type":23},{"name":43,"class":44},12,{"id":570,"slug":571,"hasResults":12,"nctId":572,"briefTitle":573,"officialTitle":573,"acronym":574,"eligibilityCriteria":575,"healthyVolunteers":12,"sex":18,"minAge":576,"maxAge":4,"enrollmentInfo":577,"targetDuration":4,"studyType":24,"phases":578,"briefSummary":579,"conditions":580,"keywords":582,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":588,"lastUpdatePostDateStruct":589,"startDateStruct":591,"completionDateStruct":593,"leadSponsor":595,"locationsCount":130},"100519268","evaluation-of-multimodal-and-non-invasive-spina-bifida-neurovessels-during-prospective-follow-up-100519268","NCT06041334","Evaluation of muLtimodal and Non-invasive SPINa Bifida Neurovessels During Prospective Follow-up","SPINLESS","Inclusion Criteria:\n\n* Spina patients consulted as part of the multidisciplinary consultation of the spina bifida rare disease reference centre;\n* Written consent to participate in the research.\n* Compulsory membership of a social security scheme\n\nExclusion Criteria:\n\n* Patients with a non-continuous trans ileal urinary diversion ;\n* Patients with enterocystoplasty;\n* Untreated bacteriuria at the time of urodynamic assessment and urine sample collection;\n* History of urinary tract tumour;\n* History of histologically proven interstitial cystitis;\n* Persons under legal protection (safeguard of justice, curatorship, guardianship);\n* Persons deprived of their liberty.\n* Women claiming to be pregnant","6 Years",{"count":111,"type":23},[26],"The aim of the study is to investigate known urinary biomarkers in order to determine whether they can be predictive of a risk of damage to the upper urinary tract and therefore the kidneys in patients with spina bifida. The risk of damage to the upper urinary tract can be calculated using the Galloway score, based on the results of the urodynamic study and retrograde urethrocystography, which all patients with spina bifida have regularly.\n\nThe urinary biomarkers studied TIMP-2 (Tissue inhibitor of metalloproteinases 2) and MMP-2 (matrix metalloproteinase-2) are potentially associated with renal degradation, but this has not yet been demonstrated.\n\nVolunteers to take part in the study will have their biomarkers measured at the time of their urodynamic assessment.",[581],"Spina Bifida",[581,583,584,585,586,587],"urinary biomarker","upper urinary tract","Galloway score","urodynamic work-up","urethrocystography","2025-12-15",{"date":590,"type":37},"2025-12-22",{"date":592,"type":37},"2024-01-18",{"date":594,"type":23},"2028-07-18",{"name":43,"class":44},{"id":597,"slug":598,"hasResults":12,"nctId":599,"briefTitle":600,"officialTitle":601,"acronym":602,"eligibilityCriteria":603,"healthyVolunteers":12,"sex":18,"minAge":20,"maxAge":4,"enrollmentInfo":604,"targetDuration":4,"studyType":24,"phases":606,"briefSummary":607,"conditions":608,"keywords":611,"overallStatus":173,"whyStopped":4,"lastUpdateSubmitDate":621,"lastUpdatePostDateStruct":622,"startDateStruct":624,"completionDateStruct":625,"leadSponsor":627,"locationsCount":4},"100607453","randomized-controlled-trial-testing-the-efficacy-of-transcranial-magnetic-stimulation-by-accelerated--high-dose-theta-burst-functional-imaging-guided-in-the-treatment-of-depression-in-elderly-subjects-with-cognitive-impairment-100607453","NCT07188753","Randomized Controlled Trial Testing the Efficacy of Transcranial Magnetic Stimulation by Accelerated & High-dose Theta-burst, Functional Imaging Guided, in the Treatment of Depression in Elderly Subjects With Cognitive Impairment","OLDEP-TBS - Randomized Controlled Trial Testing the Efficacy of Transcranial Magnetic Stimulation by Accelerated & High-dose Theta-burst, Functional Imaging Guided, in the Treatment of Depression in Elderly Subjects With Cognitive Impairment","OLDEP-TBS","Inclusion Criteria:\n\n1. Male or female, of ages ≥ 65 years at the time of screening\n2. Currently diagnosed with either Major Depressive Disorder (MDD) and meets criteria for a current Major Depressive Episode (MDE) according to the criteria defined in the Diagnosis and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5).\n3. Patients that don't meet the treatment response criteria according to antidepressant treatment history form (ATHF) for whom a switch to another ATD is required.\n4. rTMS\u002FiTBS naïve.\n5. Access to ongoing psychiatric care before and after completion of the study.\n6. Access to clinical rTMS after completion of the study.\n7. In good general health, as evidenced by medical history (i.e. any ongoing serious and vital medical condition).\n8. Having signed a free, informed and written consent\n9. Patients that have a valid health insurance and are affiliated to or beneficiary of a social security system.\n10. Montgomery and Asberg Depression Rating Scale (MADRS) score of ≥ 20 at screening.\n11. MoCA total score ≤ 26.\n12. Comply with eligibility criteria checklist (Appendix 3)\n\nExclusion Criteria:\n\n1. Major cognitive disorder according to DSM-5 criteria.\n2. The presence or diagnosis of prominent (primary) anxiety disorder, personality disorder, or dysthymia.\n3. Bipolar Affective Disorder I \\& II and primary psychotic disorders.\n4. Autism Spectrum disorder or Intellectual Disability.\n5. A diagnosis of obsessive-compulsive disorder (OCD).\n6. Current moderate or severe substance use disorder (according to DSM-5 criteria) or demonstrating signs of acute substance withdrawal.\n7. Any history of ECT (greater than 8 sessions) without meeting response criteria.\n8. No recent (during the current depressive episode) or concurrent use of a rapid acting antidepressant agent (i.e., ketamine or a course of ECT).\n9. History of significant neurologic disease, including Parkinson's or Huntington's disease, brain tumor, unexpected seizure\u002Fepilepsy disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma (having caused a coma and\u002For requiring specific hospital care, and\u002For with abnormal brain imaging).\n10. Untreated or insufficiently treated dysthyroidism (TSH range 0.4-4mUI\u002Fl).\n11. Treatment with another investigational drug or other intervention within the study period.\n12. Any other condition deemed by the PI to interfere with the study or increase risk to the participant.\n13. Contraindications to receiving rTMS (e.g., metal in head, history of seizure, known brain lesion).\n14. Contraindications to Magnetic Resonance Imaging (MRI) (ferromagnetic metal in their body).\n15. Participants taking certain psychoactive medications will be assessed for safety by the PI, due to potential for increase of seizure risk (e.g., clozapine) and change in cortical excitability (e.g. anticonvulsant, benzodiazepines). A maximum daily dose of 2mg lorazepam equivalent will be accepted.\n16. Persons referred in articles L.1121-5 to L.1121-8 and L.1122-2 of the Public Health Code: Pregnant women, women in labour and breastfeeding mothers Person deprived of liberty for judicial or administrative decision, adult person under legal protection (any form of public guardianship).\n17. Mini Mental Status Examination (MMSE) score \\\u003C 21.\n18. Current severe insomnia (must sleep a minimum of 5 hours each night before stimulation).\n19. Current mania or psychosis.\n20. Endorses clinically significant explicit suicidal cognitions (score ≥ 6 on the Beck Suicide Scale \\[BSS\\] self-report).\n21. Any current substance abuse that is clinically elicited or based on urine\u002Fbreathalyzer screening deemed by the PI to be critical from a safety standpoint.\n22. Depth-adjusted aiTBS treatment dose \\> 65% maximum stimulator output (MSO).",{"count":605,"type":23},186,[26],"This trial aims at testing a new intensive, personalized functional targeting, transcranial magnetic stimulation technique for elderly patients (aged ≥ 65 years) suffering from a current treatment resistant depressive episode to at least one antidepressant, and suffering from significant secondary cognitive impairment.\n\nThe intervention will be based on an accelerated neuromodulation technique using intermittent theta bursts (aiTBS) guided by a personalised funcitonal target within the left dorsolateral prefrontal cortex (DLPFC), using the SAINT® technology, which was recently cleared by the FDA.",[609,610],"Treatment Resistant Depression","Elderly Depression (≥65y.o.)",[612,613,614,615,616,617,618,619,620],"transcranial magentic stimulation","personalized targeting","depression","elderly","old-age depression","treatment resistant","accelerated TMS","iTBS","theta birst stimulation","2025-09-22",{"date":623,"type":37},"2025-09-23",{"date":588,"type":23},{"date":626,"type":23},"2031-12-15",{"name":43,"class":44},{"id":629,"slug":630,"hasResults":12,"nctId":631,"briefTitle":632,"officialTitle":633,"acronym":634,"eligibilityCriteria":635,"healthyVolunteers":12,"sex":214,"minAge":19,"maxAge":4,"enrollmentInfo":636,"targetDuration":4,"studyType":24,"phases":638,"briefSummary":639,"conditions":640,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":642,"lastUpdatePostDateStruct":643,"startDateStruct":645,"completionDateStruct":647,"leadSponsor":649,"locationsCount":650},"100542888","medico-economic-evaluation-of-robot-assisted-laparoscopy-compared-with-conventional-laparoscopy-in-hysterectomy-for-endometrial-cancer-100542888","NCT06348719","Medico-economic Evaluation of Robot-assisted Laparoscopy Compared With Conventional Laparoscopy in Hysterectomy for Endometrial Cancer.","Medico-economic Evaluation of Robot-assisted Laparoscopy Compared With Conventional Laparoscopy in Hysterectomy for Endometrial Cancer: Multicentre Randomised Controlled Trial","ROBOT-ECO-GYN","Randomized Study:\n\nInclusion Criteria:\n\n* Patient with low-risk or intermediate-risk endometrial carcinoma (on pre-operative workup including histology on endometrial biopsy and pelvic and lumbo-aortic MRI) , i.e. patients with endometrioid-type endometrial adenocarcinoma cancer low-grade (grade 1 or 2) and pre-therapeutic FIGO stage I (FIGO classification 2023) on MRI.\n* Indication for minimally invasive STH (laparoscopy) given by the surgeon during the pre-op consultation.\n* Patient accepts the matching of pseudonymized data with the French National Health Data System (SNDS)\n* Major patient.\n* Patient having received information on the protocol and having signed a consent form, thus accepting randomization in the robot-assisted intervention group versus conventional laparoscopy.\n\nNon Inclusion Criteria:\n\n* Patient operated on by a surgeon with less than 30 cases of robotic surgery in the last year and\u002For with less than 50 cases of total robotic experience at the time of patient inclusion.\n* Patient refuses to participate in randomized controlled trial (refuses randomization)\n* The surgeon refuses the patient's participation in the randomized controlled trial (does not wish to randomize the patient).\n* The center does not have a robot\n* The center does not have a laparoscopic column with fluorescence\n* Person under legal protection (safeguard of justice, curatorship, guardianship) or person deprived of liberty;\n* Patient not affiliated to a French social security scheme\n* Patient participating in another interventional trial or in Jardé off-label research that impacts study data, or in RIPH3 that impacts study data\n* Pregnant or breast-feeding patient\n\nExclusion criteria :\n\n* Minimally invasive procedure contraindicated by pre-operative anesthesia.\n* Patient operated on by a robot other than one of the intuitive robot variants (Si, X and Xi).\n\nProspective cohort:\n\nInclusion Criteria:\n\n* Patient with low-risk or intermediate-risk endometrial carcinoma (on pre-operative workup including histology on endometrial biopsy and pelvic and lumbo-aortic MRI) , i.e. patient with endometrioid-type endometrial adenocarcinoma cancer low-grade (grade 1 or 2) and pre-therapeutic FIGO stage I (FIGO classification 2023) on MRI .\n* Indication for minimally invasive STH (laparoscopy) given by the surgeon during the pre-op consultation.\n* Patient accepts the matching of pseudonymized data with the French National Health Data System (SNDS)\n* Major patient.\n* Patient not included in randomized controlled trial because :\n\n  * Patient refuses to participate in randomized controlled trial (refusing randomization)\n  * The surgeon refuses the patient's participation in the randomized controlled trial (does not wish to randomize the patient)\n  * The center does not have a robot\n  * The center does not have a laparoscopic column with fluorescence\n  * The surgeon does not meet the required learning curve criteria (as a reminder: ≥ 30 cases of robotic surgery in the last year and with total robotic experience ≥ 50 procedures ) at the time of patient inclusion\n* Patient has been informed about the protocol and has signed a consent form.\n\nNon Inclusion Criteria:\n\n* Person under legal protection (safeguard of justice, curatorship, guardianship) or person deprived of liberty;\n* Patient not affiliated to a French social security scheme\n* Patient participating in another interventional trial or in Jardé off-label research that impacts study data, or in RIPH3 that impacts study data\n* Pregnant or breast-feeding patient\n\nExclusion criteria :\n\n* Minimally invasive procedure contraindicated by pre-operative anesthesia.\n* Patient operated on by a robot other than one of the intuitive robot variants (Si, X and Xi).\n\nRetrospective cohort:\n\nInclusion Criteria:\n\n* Patient with low-risk or intermediate-risk endometrial carcinoma (on pre-operative workup including histology on endometrial biopsy and pelvic and lumbo-aortic MRI) , i.e. patient with endometrioid-type endometrial adenocarcinoma cancer low-grade (grade 1 or 2) and pre-therapeutic FIGO stage I (FIGO classification 2023) on MRI).\n* STH performed during the inclusion period of the randomized controlled trial and\u002For the prospective cohortat a participating center, regardless of the approach used, not included in the randomized controlled trial and in the prospective cohort.\n* Patient not objecting to the collection and use of her data\n* Patient of legal age.\n\nNon Inclusion Criteria:\n\n* Person under legal protection (safeguard of justice, curatorship, guardianship) or person deprived of liberty;\n* Patient not affiliated to a French social security scheme\n\nSurgeons :\n\nInclusion Criteria:\n\n* Surgeon performing hysterectomy on patients included in the randomized study and\u002For prospective cohort\n* Surgeon not objecting to the collection and use of his data\n\nNon- inclusion Criteria:\n\nNone\n\nFirst surgical assistance in the field :\n\nInclusion Criteria:\n\n* First surgical assistance in the field performing hysterectomy on patients included in the randomized study and\u002For prospective cohort\n* First surgical assistance in the field not objecting to the collection and use of his data\n\nNon- inclusion Criteria:\n\nNone",{"count":637,"type":23},1680,[26],"The standard treatment for endometrial cancer is surgery, as long as the stage of the disease and the patient's condition allow. It consists of hysterectomy (TSH) with bilateral adnexectomy. The recommended surgical approach is the minimally invasive or laparoscopic route, whose oncological safety has been demonstrated by the LAP2 study.\n\nSince 2010 and the arrival of robotic surgery in gynaecology, the robot-assisted laparoscopic approach has gradually been used for endometrial cancer Hysterectomy.\n\nSeveral studies have suggested that the cost and effectiveness of laparoscopy may vary according to the age and body mass index of the patient.\n\nThe investigators therefore hypothesise that robot-assisted laparoscopy may be more efficient than conventional laparoscopy for endometrial cancer hysterectomy in the context of an advanced learning curve in France.\n\nThe investigators therefore hypothesise that robot-assisted laparoscopy could be more efficient than conventional laparoscopy for endometrial cancer hysterectomy in the context of an advanced learning curve in France. The investigators will also test the efficiency of the surgical technique as a function of age and Body mass Index.",[641],"Hysterectomies for Low- or Intermediate-risk Endometrial Carcinoma","2025-09-08",{"date":644,"type":37},"2025-09-15",{"date":646,"type":37},"2024-09-23",{"date":648,"type":23},"2028-03",{"name":43,"class":44},15,{"id":652,"slug":653,"hasResults":12,"nctId":654,"briefTitle":655,"officialTitle":656,"acronym":657,"eligibilityCriteria":658,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":659,"targetDuration":4,"studyType":24,"phases":661,"briefSummary":663,"conditions":664,"keywords":668,"overallStatus":173,"whyStopped":4,"lastUpdateSubmitDate":673,"lastUpdatePostDateStruct":674,"startDateStruct":676,"completionDateStruct":677,"leadSponsor":679,"locationsCount":680},"100589129","phase-2-normothermic-oxygenated-perfusion-nmp-viability-testing-before-transplantation-of-discarded-livers-100589129","NCT06950398","Normothermic Oxygenated Perfusion (NMP) Viability Testing Before Transplantation of Discarded Livers","Normothermic Oxygenated Perfusion (NMP) Viability Testing Before Transplantation of Discarded Livers. An Open Label, Non-randomized, Prospective, Single Arm Trial","TRANSPERF","INCLUSION CRITERIA :\n\nFOR LIVER DONORS\n\n* Donation after brainstem death (DBD)\n* Liver graft refused by 5 different transplant centres and after rescue allocation (\"hors tour\")\n\nFOR LIVER TRANSPLANT RECIPIENTS\n\n* ≥ 18 years old\n* Candidates for a first elective liver transplantation (patients with a pre-transplant work-up excluding: re-transplantation, emergency transplantation (e.g. fulminant hepatitis), multi-organ or heterotopic transplantation)\n* UNOS status IV (non-ventilated, no vasopressor support)\n* Absence of renal insufficiency defined as a GFR of less than 60 mL\u002Fmin\u002F1.73 m² for three months or more\n* MELD Score ≤ 25\n* Willing and able to attend follow-up examinations\n* Having signed an informed consent document\n\nNON-INCLUSION CRITERIA:\n\nFOR LIVER DONORS\n\n* Macroscopic features of advanced fibrosis or cirrhosis at procurement\n* Transplantation using a split graft, in situ or ex situ\n* Estimated cold ischemic time greater than 8 hours (5 hours maximum of graft transport in cold ischemia)\n\nFOR LIVER TRANSPLANT RECIPIENTS\n\n* Mentally or legally incapacitated\n* Transplantation for fulminant hepatic failure\n* Early or late re-transplantation\n* Combined liver transplant with any other organ, en-bloc or not\n* Heterotopic liver transplantation",{"count":660,"type":23},99,[662],"PHASE2","Liver transplantation (LT) is a highly effective treatment for end-stage liver disease and early-stage primary liver cancer. As such, the demand for donor livers greatly exceeds supply; in 2021 in France, 12.9% of patients on the waitlist either died or were delisted for worsening of their condition.\n\nHowever a substantial number of perfectly viable organs are wrongly discarded based on a highly subjective assessment as the level of acceptance varies widely depending on the physician's judgement.\n\nThe idea of using Normothermic Machine Perfusion (NMP) not only to preserve the liver graft but also for selection purposes is a concept that has been already investigated. A few trials have analyzed the value of normothermic perfusion to assess rejected liver grafts.\n\nSeveral teams demonstrated that NMP provides a tool to assess organ viability pre-transplantation as the liver is able to maintain an almost physiological metabolism.\n\nThese preliminary results came from small samples, 45% of which originated from donation after circulatory death (DCD). They need confirmation in a larger sample of organs from donors with brainstem death (DBD), adapted to the French liver allocation system.\n\nThis trial will reproduce and confirm the results of the previous studies in order to establish viability testing as the de facto method for high-risk or rejected grafts. It will also validate existing viability markers so as to define a new standard for viability testing using NMP.",[665,666,667],"Organ Transplantation","Liver Dysfunction","Liver Diseases",[87,669,670,671,672],"Normothermic oxygenated perfusion","NMP","Discarded livers","Viability assessment","2025-08-14",{"date":675,"type":37},"2025-08-15",{"date":588,"type":23},{"date":678,"type":23},"2029-06-15",{"name":43,"class":44},6,""]